APO Research
Talk to an analyst

APO RESEARCH · REPORT

CAR T-Cell-Based Drug

Compare research editions
View pricing & licenses

Selected research

Industry Research

CAR T-Cell-Based Drug Industry Research Report 2026

20 December 2025121 pages

Choose your research edition.

Industry ResearchCAR T-Cell-Based Drug Industry Research Report 2026121 pages · $2,950 USDIndustry Growth & TrendsGlobal CAR T-Cell-Based Drug Industry Growth and Trends Forecast to 2032103 pages · $3,450 USDMarket StructureGlobal CAR T-Cell-Based Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032198 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal CAR T-Cell-Based Drug Market Outlook and Growth Opportunities 2026199 pages · $4,250 USDMarket Analysis & ForecastGlobal CAR T-Cell-Based Drug Market Analysis and Forecast 2026-2032198 pages · $4,950 USD

Market perspective

The global CAR T-Cell-Based Drug market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.

North America: the CAR T-Cell-Based Drug market is projected to increase from US$ million in 2026 to US$ million by 2032, reflecting a CAGR of % over 2026–2032. Europe: the CAR T-Cell-Based Drug market is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032. Asia Pacific: the CAR T-Cell-Based Drug market is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032. Leading global service providers of CAR T-Cell-Based Drug include J & J, Novartis, Gilead Sciences, Bristol-Myers Squibb, Sorrento Therapeutics, Mustang Bio, JW Therapeutics, FOSUNKite and Celyad, among others; in 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

Read the full market overview

This report quantifies the global CAR T-Cell-Based Drug market in terms of revenue (US$ million) and, where applicable, service volume (k units), using 2024 as the base year and providing annual historical and forecast data for 2021–2032.

It standardizes definitions of service Types and end-use Applications, harmonizes provider attribution, and delivers comparable time series by company, Type, Application, and region or country, including indicative price bands (US$/k units) and concentration ratios (CR5/CR10). Outputs are intended to support service design, budgeting, capacity planning, and benchmarking for providers, platforms, channel partners, and investors; the report also reviews technology shifts and notable service innovations relevant to CAR T-Cell-Based Drug.

Key Companies & Market Share Insights

This section profiles leading service providers with 2021–2025 results and a 2026–2032 outlook—covering revenue, market share, price bands, service portfolio and client mix, regional and channel mix, and key developments (M&A, network expansion, certifications). It also provides global revenue, average price, and—where applicable—volume metrics by provider, and calculates CR5/CR10 and rank changes to support comparative benchmarking.

CAR T-Cell-Based Drug Market by Company

J & J

Novartis

Gilead Sciences

Bristol-Myers Squibb

Sorrento Therapeutics

Mustang Bio

JW Therapeutics

FOSUNKite

Celyad

Cellectis

CARsgen Therapeutics

Bluebird Bio

Autolus Therapeutics

Allogene Therapeutics

CAR T-Cell-Based Drug Segment by Type

CD19-targeted

BCMA-targeted

CAR T-Cell-Based Drug Segment by Application

Lymphoma

Multiple Myeloma

CAR T-Cell-Based Drug Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Spain

Russia

Netherlands

Nordic Countries

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Saudi Arabia

Israel

United Arab Emirates

Turkey

Iran

Egypt

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global CAR T-Cell-Based Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of CAR T-Cell-Based Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market

5. This report helps stakeholders to gain insights into which regions to target globally

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of CAR T-Cell-Based Drug.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Research objectives, research methods, data sources, data cross-validation;

Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.

Chapter 6: Detailed analysis of CAR T-Cell-Based Drug companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 13: The main points and conclusions of the report.

More report detail

Tables and figures
List of Tables Table 1. Secondary Sources Table 2. Primary Sources Table 3. Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 4. Market Value Comparison by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 5. Global CAR T-Cell-Based Drug Market Size by Type (2021-2026) & (US$ Million) Table 6. Global CAR T-Cell-Based Drug Revenue Market Share by Type (2021-2026) Table 7. Global CAR T-Cell-Based Drug Forecasted Market Size by Type (2027-2032) & (US$ Million) Table 8. Global CAR T-Cell-Based Drug Revenue Market Share by Type (2027-2032) Table 9. Global CAR T-Cell-Based Drug Market Size by Application (2021-2026) & (US$ Million) Table 10. Global CAR T-Cell-Based Drug Revenue Market Share by Application (2021-2026) Table 11. Global CAR T-Cell-Based Drug Forecasted Market Size by Application (2027-2032) & (US$ Million) Table 12. Global CAR T-Cell-Based Drug Revenue Market Share by Application (2027-2032) Table 13. Global CAR T-Cell-Based Drug Market Size by Region (US$ Million): 2021 VS 2025 VS 2032 Table 14. Global CAR T-Cell-Based Drug Market Size by Region (2021-2026) & (US$ Million) Table 15. Global CAR T-Cell-Based Drug Market Share by Region (2021-2026) Table 16. Global CAR T-Cell-Based Drug Forecasted Market Size by Region (2027-2032) & (US$ Million) Table 17. Global CAR T-Cell-Based Drug Market Share by Region (2027-2032) Table 18. CAR T-Cell-Based Drug Industry Trends Table 19. CAR T-Cell-Based Drug Industry Drivers Table 20. CAR T-Cell-Based Drug Industry Opportunities and Challenges Table 21. CAR T-Cell-Based Drug Market Restraints Table 22. Global Top CAR T-Cell-Based Drug Players by Revenue (US$ Million) & (2021-2026) Table 23. Global CAR T-Cell-Based Drug Revenue Market Share by Players (2021-2026) Table 24. Global CAR T-Cell-Based Drug Industry Players Ranking, 2024 VS 2025 VS 2026 Table 25. Global Key Players of CAR T-Cell-Based Drug, Headquarters and Area Served Table 26. Global CAR T-Cell-Based Drug Players, Product Type & Application Table 27. Global Players Market Concentration Ratio (CR5 and HHI) Table 28. Global CAR T-Cell-Based Drug by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 29. Players Mergers & Acquisitions, Expansion Plans Table 30. North America CAR T-Cell-Based Drug Market Growth Rate by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 31. North America CAR T-Cell-Based Drug Market Size by Country (2021-2026) & (US$ Million) Table 32. North America CAR T-Cell-Based Drug Market Size by Country (2027-2032) & (US$ Million) Table 33. Europe CAR T-Cell-Based Drug Market Growth Rate by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 34. Europe CAR T-Cell-Based Drug Market Size by Country (2021-2026) & (US$ Million) Table 35. Europe CAR T-Cell-Based Drug Market Size by Country (2027-2032) & (US$ Million) Table 36. Asia Pacific CAR T-Cell-Based Drug Market Growth Rate by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 37. Asia Pacific CAR T-Cell-Based Drug Market Size by Region (2021-2026) & (US$ Million) Table 38. Asia Pacific CAR T-Cell-Based Drug Market Size by Country (2027-2032) & (US$ Million) Table 39. South America CAR T-Cell-Based Drug Market Growth Rate by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 40. South America CAR T-Cell-Based Drug Market Size by Country (2021-2026) & (US$ Million) Table 41. South America CAR T-Cell-Based Drug Market Size by Country (2027-2032) & (US$ Million) Table 42. Middle East & Africa CAR T-Cell-Based Drug Market Growth Rate by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 43. Middle East & Africa CAR T-Cell-Based Drug Market Size by Country (2021-2026) & (US$ Million) Table 44. Middle East & Africa CAR T-Cell-Based Drug Market Size by Country (2027-2032) & (US$ Million) Table 45. J & J Company Information Table 46. J & J Business Overview Table 47. J & J Revenue in CAR T-Cell-Based Drug Business (2021-2026) & (US$ Million) Table 48. J & J CAR T-Cell-Based Drug Product Portfolio Table 49. J & J Recent Developments Table 50. Novartis Company Information Table 51. Novartis Business Overview Table 52. Novartis Revenue in CAR T-Cell-Based Drug Business (2021-2026) & (US$ Million) Table 53. Novartis CAR T-Cell-Based Drug Product Portfolio Table 54. Novartis Recent Developments Table 55. Gilead Sciences Company Information Table 56. Gilead Sciences Business Overview Table 57. Gilead Sciences Revenue in CAR T-Cell-Based Drug Business (2021-2026) & (US$ Million) Table 58. Gilead Sciences CAR T-Cell-Based Drug Product Portfolio Table 59. Gilead Sciences Recent Developments Table 60. Bristol-Myers Squibb Company Information Table 61. Bristol-Myers Squibb Business Overview Table 62. Bristol-Myers Squibb Revenue in CAR T-Cell-Based Drug Business (2021-2026) & (US$ Million) Table 63. Bristol-Myers Squibb CAR T-Cell-Based Drug Product Portfolio Table 64. Bristol-Myers Squibb Recent Developments Table 65. Sorrento Therapeutics Company Information Table 66. Sorrento Therapeutics Business Overview Table 67. Sorrento Therapeutics Revenue in CAR T-Cell-Based Drug Business (2021-2026) & (US$ Million) Table 68. Sorrento Therapeutics CAR T-Cell-Based Drug Product Portfolio Table 69. Sorrento Therapeutics Recent Developments Table 70. Mustang Bio Company Information Table 71. Mustang Bio Business Overview Table 72. Mustang Bio Revenue in CAR T-Cell-Based Drug Business (2021-2026) & (US$ Million) Table 73. Mustang Bio CAR T-Cell-Based Drug Product Portfolio Table 74. Mustang Bio Recent Developments Table 75. JW Therapeutics Company Information Table 76. JW Therapeutics Business Overview Table 77. JW Therapeutics Revenue in CAR T-Cell-Based Drug Business (2021-2026) & (US$ Million) Table 78. JW Therapeutics CAR T-Cell-Based Drug Product Portfolio Table 79. JW Therapeutics Recent Developments Table 80. FOSUNKite Company Information Table 81. FOSUNKite Business Overview Table 82. FOSUNKite Revenue in CAR T-Cell-Based Drug Business (2021-2026) & (US$ Million) Table 83. FOSUNKite CAR T-Cell-Based Drug Product Portfolio Table 84. FOSUNKite Recent Developments Table 85. Celyad Company Information Table 86. Celyad Business Overview Table 87. Celyad Revenue in CAR T-Cell-Based Drug Business (2021-2026) & (US$ Million) Table 88. Celyad CAR T-Cell-Based Drug Product Portfolio Table 89. Celyad Recent Developments Table 90. Cellectis Company Information Table 91. Cellectis Business Overview Table 92. Cellectis Revenue in CAR T-Cell-Based Drug Business (2021-2026) & (US$ Million) Table 93. Cellectis CAR T-Cell-Based Drug Product Portfolio Table 94. Cellectis Recent Developments Table 95. CARsgen Therapeutics Company Information Table 96. CARsgen Therapeutics Business Overview Table 97. CARsgen Therapeutics Revenue in CAR T-Cell-Based Drug Business (2021-2026) & (US$ Million) Table 98. CARsgen Therapeutics CAR T-Cell-Based Drug Product Portfolio Table 99. CARsgen Therapeutics Recent Developments Table 100. Bluebird Bio Company Information Table 101. Bluebird Bio Business Overview Table 102. Bluebird Bio Revenue in CAR T-Cell-Based Drug Business (2021-2026) & (US$ Million) Table 103. Bluebird Bio CAR T-Cell-Based Drug Product Portfolio Table 104. Bluebird Bio Recent Developments Table 105. Autolus Therapeutics Company Information Table 106. Autolus Therapeutics Business Overview Table 107. Autolus Therapeutics Revenue in CAR T-Cell-Based Drug Business (2021-2026) & (US$ Million) Table 108. Autolus Therapeutics CAR T-Cell-Based Drug Product Portfolio Table 109. Autolus Therapeutics Recent Developments Table 110. Allogene Therapeutics Company Information Table 111. Allogene Therapeutics Business Overview Table 112. Allogene Therapeutics Revenue in CAR T-Cell-Based Drug Business (2021-2026) & (US$ Million) Table 113. Allogene Therapeutics CAR T-Cell-Based Drug Product Portfolio Table 114. Allogene Therapeutics Recent Developments Table 115. Authors List of This Report List of Figures Figure 1. Research Methodology Figure 2. Research Process Figure 3. Key Executives Interviewed Figure 4. CAR T-Cell-Based Drug Product Image Figure 5. Global CAR T-Cell-Based Drug Market Size Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 6. Global CAR T-Cell-Based Drug Market Share by Type: 2025 VS 2032 Figure 7. CD19-targeted Product Figure 8. BCMA-targeted Product Figure 9. Global CAR T-Cell-Based Drug Market Size by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 10. Global CAR T-Cell-Based Drug Market Share by Application: 2025 VS 2032 Figure 11. Lymphoma Product Figure 12. Multiple Myeloma Product Figure 13. Global CAR T-Cell-Based Drug Market Size (US$ Million), Year-over-Year: 2021-2032 Figure 14. Global CAR T-Cell-Based Drug Market Size, (US$ Million), 2021 VS 2025 VS 2032 Figure 15. Global CAR T-Cell-Based Drug Market Share by Region: 2025 VS 2032 Figure 16. Global CAR T-Cell-Based Drug Market Share by Players in 2025 Figure 17. Global CAR T-Cell-Based Drug Manufacturers Established Date Figure 18. Global Top 5 and 10 CAR T-Cell-Based Drug Players Market Share by Revenue in 2025 Figure 19. Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 20. North America CAR T-Cell-Based Drug Market Size YoY Growth (2021-2032) & (US$ Million) Figure 21. North America CAR T-Cell-Based Drug Market Share by Country (2021-2032) Figure 22. United States CAR T-Cell-Based Drug Market Size YoY Growth (2021-2032) & (US$ Million) Figure 23. Canada CAR T-Cell-Based Drug Market Size YoY Growth (2021-2032) & (US$ Million) Figure 24. Mexico CAR T-Cell-Based Drug Market Share by Country (2021-2032) Figure 25. Europe CAR T-Cell-Based Drug Market Size YoY Growth (2021-2032) & (US$ Million) Figure 26. Europe CAR T-Cell-Based Drug Market Share by Country (2021-2032) Figure 27. Germany CAR T-Cell-Based Drug Market Size YoY Growth (2021-2032) & (US$ Million) Figure 28. France CAR T-Cell-Based Drug Market Size YoY Growth (2021-2032) & (US$ Million) Figure 29. U.K. CAR T-Cell-Based Drug Market Size YoY Growth (2021-2032) & (US$ Million) Figure 30. Italy CAR T-Cell-Based Drug Market Size YoY Growth (2021-2032) & (US$ Million) Figure 31. Spain CAR T-Cell-Based Drug Market Size YoY Growth (2021-2032) & (US$ Million) Figure 32. Russia CAR T-Cell-Based Drug Market Size YoY Growth (2021-2032) & (US$ Million) Figure 33. Netherlands CAR T-Cell-Based Drug Market Size YoY Growth (2021-2032) & (US$ Million) Figure 34. Nordic Countries CAR T-Cell-Based Drug Market Size YoY Growth (2021-2032) & (US$ Million) Figure 35. Asia-Pacific CAR T-Cell-Based Drug Market Size YoY Growth (2021-2032) & (US$ Million) Figure 36. Asia-Pacific CAR T-Cell-Based Drug Market Share by Country (2021-2032) Figure 37. China CAR T-Cell-Based Drug Market Size YoY Growth (2021-2032) & (US$ Million) Figure 38. Japan CAR T-Cell-Based Drug Market Size YoY Growth (2021-2032) & (US$ Million) Figure 39. South Korea CAR T-Cell-Based Drug Market Size YoY Growth (2021-2032) & (US$ Million) Figure 40. India CAR T-Cell-Based Drug Market Size YoY Growth (2021-2032) & (US$ Million) Figure 41. India CAR T-Cell-Based Drug Market Share by Country (2021-2032) Figure 42. Australia CAR T-Cell-Based Drug Market Size YoY Growth (2021-2032) & (US$ Million) Figure 43. China Taiwan CAR T-Cell-Based Drug Market Size YoY Growth (2021-2032) & (US$ Million) Figure 44. Southeast Asia CAR T-Cell-Based Drug Market Size YoY Growth (2021-2032) & (US$ Million) Figure 45. South America CAR T-Cell-Based Drug Market Size YoY Growth (2021-2032) & (US$ Million) Figure 46. South America CAR T-Cell-Based Drug Market Share by Country (2021-2032) Figure 47. Brazil CAR T-Cell-Based Drug Market Size YoY Growth (2021-2032) & (US$ Million) Figure 48. Argentina CAR T-Cell-Based Drug Market Size YoY Growth (2021-2032) & (US$ Million) Figure 49. Chile CAR T-Cell-Based Drug Market Size YoY Growth (2021-2032) & (US$ Million) Figure 50. Colombia CAR T-Cell-Based Drug Market Size YoY Growth (2021-2032) & (US$ Million) Figure 51. Peru CAR T-Cell-Based Drug Market Size YoY Growth (2021-2032) & (US$ Million) Figure 52. J & J Revenue Growth Rate in CAR T-Cell-Based Drug Business (2021-2026) Figure 53. Novartis Revenue Growth Rate in CAR T-Cell-Based Drug Business (2021-2026) Figure 54. Gilead Sciences Revenue Growth Rate in CAR T-Cell-Based Drug Business (2021-2026) Figure 55. Bristol-Myers Squibb Revenue Growth Rate in CAR T-Cell-Based Drug Business (2021-2026) Figure 56. Sorrento Therapeutics Revenue Growth Rate in CAR T-Cell-Based Drug Business (2021-2026) Figure 57. Mustang Bio Revenue Growth Rate in CAR T-Cell-Based Drug Business (2021-2026) Figure 58. JW Therapeutics Revenue Growth Rate in CAR T-Cell-Based Drug Business (2021-2026) Figure 59. FOSUNKite Revenue Growth Rate in CAR T-Cell-Based Drug Business (2021-2026) Figure 60. Celyad Revenue Growth Rate in CAR T-Cell-Based Drug Business (2021-2026) Figure 61. Cellectis Revenue Growth Rate in CAR T-Cell-Based Drug Business (2021-2026) Figure 62. CARsgen Therapeutics Revenue Growth Rate in CAR T-Cell-Based Drug Business (2021-2026) Figure 63. Bluebird Bio Revenue Growth Rate in CAR T-Cell-Based Drug Business (2021-2026) Figure 64. Autolus Therapeutics Revenue Growth Rate in CAR T-Cell-Based Drug Business (2021-2026) Figure 65. Allogene Therapeutics Revenue Growth Rate in CAR T-Cell-Based Drug Business (2021-2026)

Scope & coverage.

Types
  • CD19-targeted
  • BCMA-targeted
Applications
  • Lymphoma
  • Multiple Myeloma
Companies covered
  • J & J
  • Novartis
  • Gilead Sciences
  • Bristol-Myers Squibb
  • Sorrento Therapeutics
  • Mustang Bio
  • JW Therapeutics
  • FOSUNKite
  • Celyad
  • Cellectis
  • CARsgen Therapeutics
  • Bluebird Bio
  • Autolus Therapeutics
  • Allogene Therapeutics

Inside the report.

1 Preface
  1. 1.1 Scope of Report
  2. 1.2 Reasons for Doing This Study
  3. 1.3 Research Methodology
  4. 1.4 Research Process
  5. 1.5 Data Source
  6. 1.5.1 Secondary Sources
  7. 1.5.2 Primary Sources
2 Market Overview
  1. 2.1 Product Definition
  2. 2.2 CAR T-Cell-Based Drug by Type
  3. 2.2.1 Market Value Comparison by Type (2021 VS 2025 VS 2032)
  4. 2.2.2 CD19-targeted
  5. 2.2.3 BCMA-targeted
  6. 2.3 CAR T-Cell-Based Drug by Application
  7. 2.3.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
  8. 2.3.2 Lymphoma
  9. 2.3.3 Multiple Myeloma
  10. 2.4 Assumptions and Limitations
3 CAR T-Cell-Based Drug Breakdown Data by Type
  1. 3.1 Global CAR T-Cell-Based Drug Historic Market Size by Type (2021-2026)
  2. 3.2 Global CAR T-Cell-Based Drug Forecasted Market Size by Type (2027-2032)
4 CAR T-Cell-Based Drug Breakdown Data by Application
  1. 4.1 Global CAR T-Cell-Based Drug Historic Market Size by Application (2021-2026)
  2. 4.2 Global CAR T-Cell-Based Drug Forecasted Market Size by Application (2027-2032)
5 Global Growth Trends
  1. 5.1 Global CAR T-Cell-Based Drug Market Perspective (2021-2032)
  2. 5.2 Global CAR T-Cell-Based Drug Growth Trends by Region
  3. 5.2.1 Global CAR T-Cell-Based Drug Market Size by Region: 2021 VS 2025 VS 2032
  4. 5.2.2 CAR T-Cell-Based Drug Historic Market Size by Region (2021-2026)
  5. 5.2.3 CAR T-Cell-Based Drug Forecasted Market Size by Region (2027-2032)
  6. 5.3 CAR T-Cell-Based Drug Market Dynamics
  7. 5.3.1 CAR T-Cell-Based Drug Industry Trends
  8. 5.3.2 CAR T-Cell-Based Drug Market Drivers
  9. 5.3.3 CAR T-Cell-Based Drug Market Challenges
  10. 5.3.4 CAR T-Cell-Based Drug Market Restraints
6 Market Competitive Landscape by Players
  1. 6.1 Global Top CAR T-Cell-Based Drug Players by Revenue
  2. 6.1.1 Global Top CAR T-Cell-Based Drug Players by Revenue (2021-2026)
  3. 6.1.2 Global CAR T-Cell-Based Drug Revenue Market Share by Players (2021-2026)
  4. 6.2 Global CAR T-Cell-Based Drug Industry Players Ranking, 2023 VS 2024 VS 2025
  5. 6.3 Global Key Players of CAR T-Cell-Based Drug Head Office and Area Served
  6. 6.4 Global CAR T-Cell-Based Drug Players, Product Type & Application
  7. 6.5 Global CAR T-Cell-Based Drug Manufacturers Established Date
  8. 6.6 Global CAR T-Cell-Based Drug Market CR5 and HHI
  9. 6.7 Global Players Mergers & Acquisition
7 North America
  1. 7.1 North America CAR T-Cell-Based Drug Market Size (2021-2032)
  2. 7.2 North America CAR T-Cell-Based Drug Market Growth Rate by Country: 2021 VS 2025 VS 2032
  3. 7.3 North America CAR T-Cell-Based Drug Market Size by Country (2021-2026)
  4. 7.4 North America CAR T-Cell-Based Drug Market Size by Country (2027-2032)
  5. 7.5 United States
  6. 7.5 United States
  7. 7.6 Canada
  8. 7.7 Mexico
8 Europe
  1. 8.1 Europe CAR T-Cell-Based Drug Market Size (2021-2032)
  2. 8.2 Europe CAR T-Cell-Based Drug Market Growth Rate by Country: 2021 VS 2025 VS 2032
  3. 8.3 Europe CAR T-Cell-Based Drug Market Size by Country (2021-2026)
  4. 8.4 Europe CAR T-Cell-Based Drug Market Size by Country (2027-2032)
  5. 8.5 Germany
  6. 8.6 France
  7. 8.7 U.K.
  8. 8.8 Italy
  9. 8.9 Spain
  10. 8.10 Russia
  11. 8.11 Netherlands
  12. 8.12 Nordic Countries
9 Asia-Pacific
  1. 9.1 Asia-Pacific CAR T-Cell-Based Drug Market Size (2021-2032)
  2. 9.2 Asia-Pacific CAR T-Cell-Based Drug Market Growth Rate by Country: 2021 VS 2025 VS 2032
  3. 9.3 Asia-Pacific CAR T-Cell-Based Drug Market Size by Country (2021-2026)
  4. 9.4 Asia-Pacific CAR T-Cell-Based Drug Market Size by Country (2027-2032)
  5. 9.5 China
  6. 9.6 Japan
  7. 9.7 South Korea
  8. 9.8 India
  9. 9.9 Australia
  10. 9.10 China Taiwan
  11. 9.11 Southeast Asia
10 South America
  1. 10.1 South America CAR T-Cell-Based Drug Market Size (2021-2032)
  2. 10.2 South America CAR T-Cell-Based Drug Market Growth Rate by Country: 2021 VS 2025 VS 2032
  3. 10.3 South America CAR T-Cell-Based Drug Market Size by Country (2021-2026)
  4. 10.4 South America CAR T-Cell-Based Drug Market Size by Country (2027-2032)
  5. 10.5 Brazil
  6. 10.6 Argentina
  7. 10.7 Chile
  8. 10.8 Colombia
  9. 10.9 Peru
11 Middle East & Africa
  1. 11.1 Middle East & Africa CAR T-Cell-Based Drug Market Size (2021-2032)
  2. 11.2 Middle East & Africa CAR T-Cell-Based Drug Market Growth Rate by Country: 2021 VS 2025 VS 2032
  3. 11.3 Middle East & Africa CAR T-Cell-Based Drug Market Size by Country (2021-2026)
  4. 11.4 Middle East & Africa CAR T-Cell-Based Drug Market Size by Country (2027-2032)
  5. 11.5 Saudi Arabia
  6. 11.6 Israel
  7. 11.7 United Arab Emirates
  8. 11.8 Turkey
  9. 11.9 Iran
  10. 11.10 Egypt
12 Players Profiled
  1. 12.1 J & J
  2. 12.1.1 J & J Company Information
  3. 12.1.2 J & J Business Overview
  4. 12.1.3 J & J Revenue in CAR T-Cell-Based Drug Business (2021-2026)
  5. 12.1.4 J & J CAR T-Cell-Based Drug Product Portfolio
  6. 12.1.5 J & J Recent Developments
  7. 12.2 Novartis
  8. 12.2.1 Novartis Company Information
  9. 12.2.2 Novartis Business Overview
  10. 12.2.3 Novartis Revenue in CAR T-Cell-Based Drug Business (2021-2026)
  11. 12.2.4 Novartis CAR T-Cell-Based Drug Product Portfolio
  12. 12.2.5 Novartis Recent Developments
  13. 12.3 Gilead Sciences
  14. 12.3.1 Gilead Sciences Company Information
  15. 12.3.2 Gilead Sciences Business Overview
  16. 12.3.3 Gilead Sciences Revenue in CAR T-Cell-Based Drug Business (2021-2026)
  17. 12.3.4 Gilead Sciences CAR T-Cell-Based Drug Product Portfolio
  18. 12.3.5 Gilead Sciences Recent Developments
  19. 12.4 Bristol-Myers Squibb
  20. 12.4.1 Bristol-Myers Squibb Company Information
  21. 12.4.2 Bristol-Myers Squibb Business Overview
  22. 12.4.3 Bristol-Myers Squibb Revenue in CAR T-Cell-Based Drug Business (2021-2026)
  23. 12.4.4 Bristol-Myers Squibb CAR T-Cell-Based Drug Product Portfolio
  24. 12.4.5 Bristol-Myers Squibb Recent Developments
  25. 12.5 Sorrento Therapeutics
  26. 12.5.1 Sorrento Therapeutics Company Information
  27. 12.5.2 Sorrento Therapeutics Business Overview
  28. 12.5.3 Sorrento Therapeutics Revenue in CAR T-Cell-Based Drug Business (2021-2026)
  29. 12.5.4 Sorrento Therapeutics CAR T-Cell-Based Drug Product Portfolio
  30. 12.5.5 Sorrento Therapeutics Recent Developments
  31. 12.6 Mustang Bio
  32. 12.6.1 Mustang Bio Company Information
  33. 12.6.2 Mustang Bio Business Overview
  34. 12.6.3 Mustang Bio Revenue in CAR T-Cell-Based Drug Business (2021-2026)
  35. 12.6.4 Mustang Bio CAR T-Cell-Based Drug Product Portfolio
  36. 12.6.5 Mustang Bio Recent Developments
  37. 12.7 JW Therapeutics
  38. 12.7.1 JW Therapeutics Company Information
  39. 12.7.2 JW Therapeutics Business Overview
  40. 12.7.3 JW Therapeutics Revenue in CAR T-Cell-Based Drug Business (2021-2026)
  41. 12.7.4 JW Therapeutics CAR T-Cell-Based Drug Product Portfolio
  42. 12.7.5 JW Therapeutics Recent Developments
  43. 12.8 FOSUNKite
  44. 12.8.1 FOSUNKite Company Information
  45. 12.8.2 FOSUNKite Business Overview
  46. 12.8.3 FOSUNKite Revenue in CAR T-Cell-Based Drug Business (2021-2026)
  47. 12.8.4 FOSUNKite CAR T-Cell-Based Drug Product Portfolio
  48. 12.8.5 FOSUNKite Recent Developments
  49. 12.9 Celyad
  50. 12.9.1 Celyad Company Information
  51. 12.9.2 Celyad Business Overview
  52. 12.9.3 Celyad Revenue in CAR T-Cell-Based Drug Business (2021-2026)
  53. 12.9.4 Celyad CAR T-Cell-Based Drug Product Portfolio
  54. 12.9.5 Celyad Recent Developments
  55. 12.10 Cellectis
  56. 12.10.1 Cellectis Company Information
  57. 12.10.2 Cellectis Business Overview
  58. 12.10.3 Cellectis Revenue in CAR T-Cell-Based Drug Business (2021-2026)
  59. 12.10.4 Cellectis CAR T-Cell-Based Drug Product Portfolio
  60. 12.10.5 Cellectis Recent Developments
  61. 12.11 CARsgen Therapeutics
  62. 12.11.1 CARsgen Therapeutics Company Information
  63. 12.11.2 CARsgen Therapeutics Business Overview
  64. 12.11.3 CARsgen Therapeutics Revenue in CAR T-Cell-Based Drug Business (2021-2026)
  65. 12.11.4 CARsgen Therapeutics CAR T-Cell-Based Drug Product Portfolio
  66. 12.11.5 CARsgen Therapeutics Recent Developments
  67. 12.12 Bluebird Bio
  68. 12.12.1 Bluebird Bio Company Information
  69. 12.12.2 Bluebird Bio Business Overview
  70. 12.12.3 Bluebird Bio Revenue in CAR T-Cell-Based Drug Business (2021-2026)
  71. 12.12.4 Bluebird Bio CAR T-Cell-Based Drug Product Portfolio
  72. 12.12.5 Bluebird Bio Recent Developments
  73. 12.13 Autolus Therapeutics
  74. 12.13.1 Autolus Therapeutics Company Information
  75. 12.13.2 Autolus Therapeutics Business Overview
  76. 12.13.3 Autolus Therapeutics Revenue in CAR T-Cell-Based Drug Business (2021-2026)
  77. 12.13.4 Autolus Therapeutics CAR T-Cell-Based Drug Product Portfolio
  78. 12.13.5 Autolus Therapeutics Recent Developments
  79. 12.14 Allogene Therapeutics
  80. 12.14.1 Allogene Therapeutics Company Information
  81. 12.14.2 Allogene Therapeutics Business Overview
  82. 12.14.3 Allogene Therapeutics Revenue in CAR T-Cell-Based Drug Business (2021-2026)
  83. 12.14.4 Allogene Therapeutics CAR T-Cell-Based Drug Product Portfolio
  84. 12.14.5 Allogene Therapeutics Recent Developments
13 Report Conclusion
    14 Disclaimer

      GET THE RESEARCH

      Choose your license.

      Choose who needs access.
      All options are for this report and research series.

      Compare access permissions.

      Single User License
      One named user. Individual access.
      Multi User License
      Up to 5 users in the same department.
      Enterprise License
      Organization-wide access within the agreed license.

      Access applies to the purchased edition. Later editions are separate purchases.

      License options
      $2,950USD
      Buy now

      PDF by email within 3–5 working days after payment confirmation.

      Talk to an analyst
      APO Research
      Talk to an analyst